Amoxicillin Sodium for Injection with GMP Certificate

• Customization: Available
• Transport Package: 50vials/Box, 20box/Carton
• Specification: 50*26*32 CM
• Model NO.: 0.25g, 0.5g, 1.0g
• Trademark: Reyoung
• Origin: China
• Production Capacity: 200, 000, 000 Per Year

Product Description

Amoxicillin is suitable for patients with the following infection caused by sensitive bacteria (not producing -lactamase strain), whose condition is serious and need to be hospitalized or cannot be taken orally.1.Upper respiratory tract infection such as otitis media, sinusitis, pharyngitis, tonsillitis caused by Streptococcus haemolyticus, Streptococcus pneumoniae, Staphylococcus or Haemophilus influenzae.2.Urogenital tract infection caused by Escherichia coli, Proteus chia or Enterococcus faecalis.

3.Skin and soft tissue infection caused by Streptococcus haemolyticus, Staphylococcus or Escherichia coli.4.Lower respiratory tract infection such as acute bronchitis and pneumonia caused by Streptococcus haemolyticus, Streptococcus pneumoniae, Staphylococcus or Haemophilus influenzae.5.This product can also be used to treat typhoid and leptospirosis.

Reyoung Pharmaceutical Co., Ltd., established in 1966, is one of the leading manufacturer and distributor of pharmaceutical products in China. Reyoung Pharma is an GMP, ISO9001, ISO14001, OHS18001 authentication enterprise and so on. The trademark "REYOUNG" is famous trademark of China.
Reyoung Pharma has three main factories which covers an area of 1,000,000 square meters and owns total asset of more than 1.5 billion USD dollar. There is more than 5000 staff in Reyoung Pharma, of whom approximate 21 percent of the total staff is sales & marketing personnel. Reyoung Pharma has 30 workshops that can produce ten categories and more than 400 specifications of pharmaceutical products including tablets, capsules, granules, sterile active ingredients, small volume injection, powder for injection, lyophilized powder for injection, suppository, traditional Chinese medicine and aerosol. The annual production capacity can reach 2.5 billion vials of powder for injection, 300 million ampoules of liquid injection, 4 billion tablets, 6 billion capsules and 200 million bags granule of solid formulation, and 2000 tons API respectively. As a professional pharmaceutical manufacturer, Reyoung Pharma is the first enterprise to manufacture powder for injection in Shandong province. The sales and marketing network for its products covers all the big and medium cities through the mainland of PRC and also has been successfully covered more than 70 countries all over the world. In order to praise Reyoung Pharma making so much contribution to Chinese pharmaceutical industry, the government granted many awards and certifications, such as state-focused high & new tech enterprise of China, national contract-stressing and promise-keeping enterprise of China, the production base of cephalosporin raw material, advanced Collective of pharmaceutical industry of Shandong province and so on.
Reyoung Pharma commenced international business and exported products in 1997. Reyoung Pharma, with an excellent sales&documentation team, owned over 20 years experience in the international transaction and registered products in different countries. Reyoung Pharma has passed the GMP inspection of Colombia, Peru, Congo, Ethiopia, Uganda, Nigeria, Ghana, Tanzania, Kenya, Cote d′Ivoire, Pakistan, Ukraine, Philippines, Cambodia, etc. Products have been exported to Asia, South America, Africa, CIS Countries, Middle East and Europe including Thailand, Philippines, Cambodia, Hong Kong, Vietnam, India, Pakistan, Colombia, Peru, Chile, Costa Rica, Venezuela, Congo, Ethiopia, Uganda, Nigeria, Tanzania, Kenya, Cameroon, Russia, Kazakhstan, Ukraine, Uzbekistan, Georgia, Yemen, Iraq, Germany, Denmark, and so on.
Look into the future, as entering into the market successively of the new products, the product structure of Reyoung Pharma will be upgraded, the producing levels and the market-controlling power will be enhanced further, and Reyoung Pharma will provide a wider platform for our old and new friends to go hand in hand and seek common development.